Literature DB >> 9548008

Mitochondrial DNA in stroke and migraine with aura.

J Ojaimi1, S Katsabanis, S Bower, A Quigley, E Byrne.   

Abstract

Patients presenting with thrombotic stroke of unexplained etiology and or migraine with aura were screened for mitochondrial (mt) DNA mutations associated with cytopathies given that both migraine and stroke-like episodes are recognised with certain mt DNA mutations. Mutations usually associated with either mitochondrial encephalopathy, lactic acidosis and stroke-like episode, myoclonic epilepsy with ragged red fibres, or those strongly linked to Leber's hereditary optic neuropathy (LHON) were not detected in patients or controls. However, increased levels of two of the secondary LHON mutations were found. The T-->C mutation at nucleotide 4216 was more common than expected in patients aged 35 years or less, as was the 13708 G-->A mutation in young stroke patients. This data lends support to the possibility that an accumulation of minor mt DNA mutations may contribute to the pathoaetiology of stroke and migraine with aura in some young patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548008     DOI: 10.1159/000015826

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

Review 1.  Headache and the risk of stroke.

Authors:  Pekka Jousilahti
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

2.  The primary headaches: genetics, epigenetics and a behavioural genetic model.

Authors:  Pasquale Montagna
Journal:  J Headache Pain       Date:  2008-03-15       Impact factor: 7.277

3.  Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study.

Authors:  Richard G Boles; Mary R Lovett-Barr; Amy Preston; B Uk Li; Kathleen Adams
Journal:  BMC Neurol       Date:  2010-01-28       Impact factor: 2.474

Review 4.  The metabolic face of migraine - from pathophysiology to treatment.

Authors:  Elena C Gross; Marco Lisicki; Dirk Fischer; Peter S Sándor; Jean Schoenen
Journal:  Nat Rev Neurol       Date:  2019-10-04       Impact factor: 42.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.